Use of dabigatran etexilate for preventing thromboembolic complications in hip joint arthroplasty

Authors

DOI:

https://doi.org/10.15674/0030-59872012494-98

Keywords:

endoprosthesis replacement, thrombosis, prophylaxis, anticoagulants

Abstract

The article deals with results of using dabigatran etexilate mesylate, a direct inhibitor of thrombin, with a preventive purpose following primary hip joint arthroplasty. After an examination, performed on 30 patients, the efficacy of dabigatran etexilate mesylate for reducing the manifestation rate of thrombosis of veins on the lower extremities was confirmed. Besides, no significant changes in the haematological and biochemical indices of blood against a background of its use were observed.

References

  1. Профилактика тромбоэмболических осложнений в травматологии и ортопедии: метод. рекомендации; [под ред. академика РАМН Ю. Л. Шевченко] / Р. М. Тихилов, Ю. М. Стойко, М. Н. Замятин, С. А. Божкова. — М., 2006. — 20 с.
  2. Фурман Н. В. Значение определения уровня D-димера плазмы крови для диагностики тромбоэмболии легочной артерии / Н. В. Фурман, А. Р. Киселев, П. Я. Довгалевский // Медицина неотложных состояний. — 2008 — № 3 (16). — С. 69–91.
  3. Закон України № 329 вiд 15.06.2007 р. [електронний ресурс] / МОЗ України. — Офіц. веб-сайт. — Режим доступу до документа: http: // www.moz.gov.ua/ua/portal/dn_20070615_329.html.
  4. American Academy of Orthopaedic Surgeons. American Academy of Orthopaedic Surgeons clinical guideline on prevention of pulmonary embolism in patients undergoing total hip or knee arthroplasty. — 2007 May. Accessed 2008. — Oct 20.
  5. Prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with low-molecular-weight heparin thrombosis / C. W. Colwell, M. I. Froimson, M. A. Mont et al. // The Journal of Bone & Joint Surgery. — 2010. — Vol. 92-A. — P. 527–535.
  6. Lieberman J. R. Prevention of venous thromboembolic disease after total hip and knee arthroplasty / J. R. Lieberman, W. K. Hsu // The Journal of Bone & Joint Surgery. — 2005. — Vol. 87-A. — P. 2097–2112.
  7. Pharmacological basis and clinical evidence of dabigatran therapy / S. Redondo, M. P. Martínez, M. Ramajo et al. // Journal Hematology & Oncology. — 2011. — Vol. 4, № 53. — P. 2097–2112.
  8. Meta-analyses in joint arthroplasty: a review of quantity, quality, and impact / R. Sharma, C. Vannabouathong, S. Bains et al. // The Journal of Bone & Joint Surgery. — 2011. — Vol. 93-A, № 24. — P. 2304–2309.

Downloads

How to Cite

Korzh, M., Filipenko, V., Leontyeva, F., Tankut, O., Malyk, R., & Yakovenko, N. (2012). Use of dabigatran etexilate for preventing thromboembolic complications in hip joint arthroplasty. ORTHOPAEDICS TRAUMATOLOGY and PROSTHETICS, (4), 94–98. https://doi.org/10.15674/0030-59872012494-98

Issue

No. 4 (2012)

Section

ORIGINAL ARTICLES

License

Copyright (c) 2014 Mykola Korzh, Volodymyr Filipenko, Frieda Leontyeva, Olexiy Tankut, Roman Malyk, Nina Yakovenko

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The authors retain the right of authorship of their manuscript and pass the journal the right of the first publication of this article, which automatically become available from the date of publication under the terms of Creative Commons Attribution License, which allows others to freely distribute the published manuscript with mandatory linking to authors of the original research and the first publication of this one in this journal.

Authors have the right to enter into a separate supplemental agreement on the additional non-exclusive distribution of manuscript in the form in which it was published by the journal (i.e. to put work in electronic storage of an institution or publish as a part of the book) while maintaining the reference to the first publication of the manuscript in this journal.

The editorial policy of the journal allows authors and encourages manuscript accommodation online (i.e. in storage of an institution or on the personal websites) as before submission of the manuscript to the editorial office, and during its editorial processing because it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the published manuscript citation (see The Effect of Open Access).